aliskiren + valsartan + hydrochlorothiazide

**aliskiren + valsartan + hydrochlorothiazide** is an oral fixed-dose combination of three antihypertensive agents used for the treatment of hypertension not adequately controlled by monotherapy or dual therapy. It includes: - **Aliskiren**, a direct renin inhibitor that inhibits the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity (PRA) and blocking the upstream step of the renin-angiotensin-aldosterone system (RAAS). - **Valsartan**, an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone secretion associated with angiotensin II. - **Hydrochlorothiazide**, a thiazide diuretic that promotes renal excretion of sodium and water, reducing blood volume and peripheral vascular resistance. The triple combination targets multiple compensatory pathways in blood pressure regulation, providing additive antihypertensive efficacy compared to monotherapy or dual combinations, particularly in patients who do not respond to monotherapy[1][3][5]. Clinical studies demonstrate significantly greater blood pressure reductions and higher rates of achieving blood pressure targets compared to HCTZ alone, or dual combinations[3][5]. Safety and tolerability are generally similar to dual combinations, with the most common adverse events including dizziness, headache, diarrhea, and infrequently, electrolyte disturbances or increases in potassium[3][5]. This triple combination is typically considered for resistant or severe hypertension[3][5].